<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Sci Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id>
<journal-title-group>
<journal-title>Scientific Reports</journal-title>
</journal-title-group>
<issn pub-type="epub">2045-2322</issn>
<publisher>
<publisher-name>Nature Publishing Group UK</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32632326</article-id>
<article-id pub-id-type="pmc">7338407</article-id>
<article-id pub-id-type="publisher-id">67946</article-id>
<article-id pub-id-type="doi">10.1038/s41598-020-67946-y</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>FMR1</italic> locus isoforms: potential biomarker candidates in fragile X-associated tremor/ataxia syndrome (FXTAS)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zafarullah</surname>
<given-names>Marwa</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tang</surname>
<given-names>Hiu-Tung</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Durbin-Johnson</surname>
<given-names>Blythe</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fourie</surname>
<given-names>Emily</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hessl</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rivera</surname>
<given-names>Susan M.</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tassone</surname>
<given-names>Flora</given-names>
</name>
<address>
<email>ftassone@ucdavis.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution>Department of Biochemistry and Molecular Medicine, School of Medicine, </institution><institution>University of California Davis, </institution></institution-wrap>Sacramento, 95817 CA USA </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution>Division of Biostatistics, School of Medicine, </institution><institution>University of California Davis, </institution></institution-wrap>Davis, CA USA </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 9684</institution-id><institution-id institution-id-type="GRID">grid.27860.3b</institution-id><institution>Center for Mind and Brain, </institution><institution>University of California Davis, </institution></institution-wrap>Davis, CA USA </aff>
<aff id="Aff4"><label>4</label>Department of Psychology, University of California, Davis, Davis, CA USA </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9752 8549</institution-id><institution-id institution-id-type="GRID">grid.413079.8</institution-id><institution>MIND Institute, University of California Davis Medical Center, </institution></institution-wrap>Sacramento, 95817 CA USA </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9752 8549</institution-id><institution-id institution-id-type="GRID">grid.413079.8</institution-id><institution>Department of Psychiatry and Behavioral Sciences, </institution><institution>University of California Davis Medical Center, </institution></institution-wrap>Sacramento, 95817 CA USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>6</day>
<month>7</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>6</day>
<month>7</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>10</volume>
<elocation-id>11099</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>12</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>5</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2020</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Fragile X associated tremor/ataxia syndrome (FXTAS) is a late adult-onset neurodegenerative disorder that affects movement and cognition in male and female carriers of a premutation allele of 55–200 CGG repeats in the Fragile X mental retardation (<italic>FMR1)</italic> gene. It is currently unknown if and when an individual carrier of a premutation allele will develop FXTAS, as clinical assessment fails to identify carriers at risk before significant neurological symptoms are evident. The primary objective of this study was to investigate the alternative splicing landscape at the <italic>FMR1</italic> locus in conjunction with brain measures in male individuals with a premutation allele enrolled in a very first longitudinal study, compared to age-matched healthy male controls, with the purpose of identifying biomarkers for early diagnosis, disease prediction and, a progression of FXTAS. Our findings indicate that increased expression of <italic>FMR1</italic> mRNA isoforms, including <italic>Iso4/4b</italic>, <italic>Iso10/10b</italic>, as well as of the <italic>ASFMR1 mRNAs Iso131bp</italic>, are present in premutation carriers as compared to non-carrier healthy controls. More specifically, we observed a higher expression of <italic>Iso4/4b and Iso10/10b,</italic> which encode for truncated proteins<italic>,</italic> only in those premutation carriers who developed symptoms of FXTAS over time as compared to non-carrier healthy controls, suggesting a potential role in the development of the disorder. In addition, we found a significant association of these molecular changes with various measurements of brain morphology, including the middle cerebellar peduncle (MCP), superior cerebellar peduncle (SCP), pons, and midbrain, indicating their potential contribution to the pathogenesis of FXTAS. Interestingly, the high expression levels of <italic>Iso4/4b</italic> observed both at visit 1 and visit 2 and found to be associated with a decrease in mean MCP width only in those individuals who developed FXTAS over time, suggests their role as potential biomarkers for early diagnosis of FXTAS.</p>
</abstract>
<kwd-group kwd-group-type="npg-subject">
<title>Subject terms</title>
<kwd>Genetics</kwd>
<kwd>Biomarkers</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par2">The fragile X mental retardation (<italic>FMR1</italic>) gene consists of 17 exons spanning approximately 38 kb of genomic DNA. A trinucleotide repeat expansion, greater than 200 CGG, with consequent methylation of the 5′UTR (untranslated region) of <italic>FMR1</italic> gene, leads to Fragile X Syndrome (FXS), the most common form of intellectual disability and known monogenic cause of Autism Spectrum Disorder<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Expansions between 55 and 200 CGG repeats (known as premutation carriers) confer the risk of developing Fragile X-associated tremor/ataxia syndrome (FXTAS), a late-onset neurodegenerative disorder characterized by intention tremor, gait ataxia, autonomic dysfunction, and Parkinsonism<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. In addition, females premutation carriers are at risk of developing Fragile X-associated primary ovarian insufficiency (FXPOI) that affects ovary function in women leading to early menopause and irregular elevation of follicle-stimulating hormone (FSH)<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. The prevalence of the premutation allele among the general population is 1:110–200 females and 1:430 males with an estimated 40–75% of males and 8–16% of females developing FXTAS<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>.</p>
<p id="Par3">At the molecular level, FXTAS is characterized by an increased level of <italic>FMR1</italic> mRNA containing expanded CGG repeats<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. The proposed molecular mechanisms of FXTAS pathogenesis include the sequestration of CGG binding proteins by the elevated levels of <italic>FMR1</italic> mRNA leading to RNA toxicity, the production of toxic FMRPolyG protein due to RAN translation and the chronic activation of DNA damage response [reviewed in<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>].</p>
<p id="Par4">Extensive alternative splicing of the <italic>FMR1</italic> gene has been observed<sup><xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR16">16</xref></sup>. Alternative splicing (AS) is a regulated process occurring during gene expression that increases protein diversity and represents a powerful evolutionary resource. It regulates the protein localization, enzymatic properties, stability, interaction with ligands and membranes<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> and is common in the nervous system playing a major role in neurogenesis, brain development<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup> and cell survival<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. It is increasingly recognized that disruption of the splicing process, which is regulated by different splicing factors, can contribute to a number of neurological disorders<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup> including autism spectrum disorder (ASD)<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>, Parkinson’s disease<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>, dementia<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, spinal muscular atrophy (SMA)<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>, Prader-Willi syndrome (PWS)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>, schizophrenia<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>, myotonic dystrophy<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>, amyotrophic lateral sclerosis<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup> and Alzheimer’s disease<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>.</p>
<p id="Par5">In the <italic>FMR1</italic> gene, altered splicing has been observed in premutation carriers where increased levels of the <italic>FMR1</italic> isoforms have been detected<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. Of the many <italic>FMR1</italic> mRNA isoforms that were demonstrated to exist in both humans and mice<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR16">16</xref></sup>, <italic>Iso10/10b</italic> showed the highest levels of expression in premutation samples which, together with the <italic>Iso4/4b</italic> (Fig. <xref ref-type="fig" rid="Fig1">1</xref>), result in truncated proteins that lack the function of the nuclear export signal (NES) and RGG box<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Of the 49 different <italic>FMR1</italic> isoforms identified, 30 appeared to be expressed only in premutation carriers compared to controls<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Additionally, two novel isoforms <italic>IsoPB1.50</italic> and <italic>IsoPB1.21</italic> retain a portion of the intronic sequence between exons 9 and 10, causing a frameshift, which leads to a premature stop codon and consequently encodes for truncated proteins. A differential increase of specific <italic>FMR1</italic> mRNA isoforms has been observed in premutation carriers, suggesting their potential functional relevance in the pathology of FXTAS due to RNA toxicity<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>.<fig id="Fig1"><label>Figure 1</label><caption><p>Schematic overview of the <italic>FMR1</italic> and <italic>ASFMR1</italic> isoforms. Diagram representing the <italic>FMR1</italic> locus (top), 4 <italic>FMR1</italic> isoforms (<italic>Iso10, Iso10b, Iso4 and Iso4b)</italic> and the <italic>ASFMR1 Iso131bp</italic>. Exons are represented in different colors and the alternative splice sites are depicted for exon 12, 14,15 and 17. <italic>FMR1</italic> isoforms <italic>Iso10,</italic> and <italic>Iso10b</italic> both miss exon 12 and 14 but differ for the splicing acceptor site in exon 17. Likewise, the <italic>FMR1 Iso4,</italic> and <italic>Iso4b</italic> both miss exon 14 but differ for the splicing acceptor site in exon 17.</p></caption><graphic id="MO1" xlink:href="41598_2020_67946_Fig1_HTML"></graphic></fig></p>
<p id="Par6">Comprehensive analysis of the transcriptional landscape of the human <italic>FMR1</italic> gene revealed the presence of long non-coding RNAs (<italic>FMR4</italic><sup><xref ref-type="bibr" rid="CR33">33</xref></sup>, <italic>FMR5</italic> and <italic>FMR6</italic>)<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. Importantly, a unique antisense transcript at the <italic>FMR1</italic> locus (<italic>ASFMR1</italic>), that similarly to the <italic>FMR1</italic> gene, is upregulated in premutations and not expressed in full mutations, has been identified. Thus, the bidirectional expression of the <italic>FMR1</italic> and the <italic>ASFMR1</italic> genes has been suggested to potentially contribute to the clinical phenotype of FXTAS<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Interestingly, the <italic>ASFMR1</italic> also exhibits a premutation specific alternative splicing, the <italic>Iso131bp</italic> (Fig. <xref ref-type="fig" rid="Fig1">1</xref>)<italic>,</italic> which is mainly expressed in premutation carriers compared to controls, providing a molecular abnormality potentially associated with FXTAS<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR36">36</xref>–<xref ref-type="bibr" rid="CR38">38</xref></sup>. However, no studies have been conducted to determine whether altered expression <italic>FMR1</italic> and <italic>ASFMR1 isoforms</italic> are biomarkers of incipient FXTAS, particularly in relation to neurological and neuroanatomical changes.</p>
<p id="Par7">In this study, we evaluated male premutation carriers enrolled in a longitudinal study at the UC Davis MIND Institute who have been followed for at least two longitudinal time points, and for whom neuroimaging, neuropsychological, and molecular measurements, as well as medical and neurological examinations, were collected. We have recently reported that the middle cerebellar peduncle (MCP) width decreased in a subgroup of these individuals who developed symptoms of FXTAS at subsequent visits (converters) compared to those who did not (non-converters) and compared to normal age-matched controls. Further, we reported reduced midbrain and pons cross-sectional areas in patients with FXTAS compared to both premutation carriers without FXTAS and controls<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. These regions play an important role within the cortico-cerebellar pathway, which is necessary for the learning and coordination of various movements<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Measurements of these areas have been shown previously to successfully differentiate subcortical movement disorders, such as Parkinson’s disease<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>, which presents with tremor similar to that seen in FXTAS.</p>
<p id="Par8">In the current study, we sought to determine whether the expression levels of alternative splicing isoforms at the <italic>FMR1</italic> locus were significantly different both in premutation carriers who did and did not develop symptoms of FXTAS over time compared to non-carrier healthy controls. In addition, we also investigated whether the changes in molecular measures were associated with changes in brain measures.</p>
</sec>
<sec id="Sec2">
<title>Materials and methods</title>
<sec id="Sec3">
<title>Study participants</title>
<p id="Par9">As part of two continuing longitudinal studies, male participants over the age of 40 years were recruited from the Sacramento, CA area, and throughout the United States and Canada. The study and all experimental protocols were carried out in accordance with the Institutional Review Board (IRB) at the University of California, Davis with written informed consent obtained from all participants in accordance with the Declaration of Helsinki. Participants were fluent in English, with no history of any serious medical or neurological conditions, including a history of alcoholism or drug abuse. FXTAS stage scoring was based on the clinical descriptions as previously described<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>.</p>
<p id="Par10">Three groups were included in this study: converters, non-converters, and healthy controls. They were matched by age and the length of the interval between visit 1 (V1) and visit 2 (V2); the converters and non-converters groups were also matched by CGG repeat number and they were selected on the basis of the brain measures availability. After two brain scans, on the basis of neurological assessment, FXTAS stage, and CGG repeat length, 15 participants were classified as “<italic>Converters”</italic> as they developed clear FXTAS symptomology between visits (FXTAS stage score was 0–1 at visit 1 and ≥ 2 at visit 2; 15 were defined as “<italic>Non-converters”</italic> because they continued to show no signs of FXTAS at V2 (FXTAS stage score was 0–1 at both V1 and V2) and 15 non-carrier healthy controls (FXTAS stage score was 0 at both V1and V2).</p>
</sec>
<sec id="Sec4">
<title>CGG repeat length</title>
<p id="Par11">Genomic DNA (gDNA) was isolated from 5 mL of peripheral blood leukocytes using the Gentra Puregene Blood Kit (Qiagen, Valencia, CA, United States). CGG repeat allele size and methylation status were assessed using a combination of Southern Blot analysis and PCR amplification. For Southern blot analysis, 5–10 μg of isolated genomic DNA was digested with EcoRI and NruI, run on an agarose gel, transferred on a nylon membrane and hybridized with the <italic>FMR1</italic>-specific dig-labeled StB12.3 as detailed in<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. PCR analysis was performed using <italic>FMR1</italic> specific primers (AmplideX PCR/CE, Asuragen, Inc.); amplicons were visualized by capillary electrophoresis, as previously reported an analyzed using Gene Mapper software<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>.</p>
</sec>
<sec id="Sec5">
<title>mRNA expression levels</title>
<p id="Par12">Total RNA was isolated from 2.5 ml of peripheral blood collected in PAXgene Blood RNA tubes using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA, United States) and quantified using Agilent 2,100 Bioanalyzer system. RNA isolation was performed in a clean and RNA designated area. cDNA was synthesized as previously described<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. <italic>FMR1</italic> transcript levels measured by performing reverse transcription followed by real-time PCRs (qRT-PCR). qRT-PCR was performed using both Assays-On-Demand from Applied Biosystems (Applied Biosystems, Foster City, CA, United States) and custom-designed TaqMan primers and probe assays,<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Probe and primer assays designed to quantify <italic>FMR1</italic> transcripts for the isoform <italic>IsoPB1.21 and IsoPB1.50</italic>, isoform <italic>Iso4/4b</italic> and isoform <italic>Iso10/10b</italic> were as previously reported<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Custom designed primers and probe were also designed to quantify the <italic>ASFMR1</italic> gene and <italic>ASFMR1 131 bp</italic> splice isoform<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>.</p>
</sec>
<sec id="Sec6">
<title>Brain measures</title>
<p id="Par13">The following methods including MRI acquisition and MRPI analysis were originally described in our previous report<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. High resolution structural magnetic resonance imaging (MRIs) acquisition was obtained on a 3 T Siemens Trio scanner using a 32-channel head coil and a T1-weighted 3D MPRAGE sequence with the following parameters: TR = 2170 ms, TE = 4.86 ms, flip angle = 7º, FoV = 256mm<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>, 192 slices, 1 mm slice thickness. The scans were first aligned along the anterior–posterior commissure line using acpcdetect (<ext-link ext-link-type="uri" xlink:href="https://www.nitrc.org/projects/art">https://www.nitrc.org/projects/art</ext-link>)<sup><xref ref-type="bibr" rid="CR46">46</xref></sup> or manually using DTI Studio (<ext-link ext-link-type="uri" xlink:href="http://www.mristudio.org">www.mristudio.org</ext-link>)<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. Then MRI bias field correction was performed using N4 (<ext-link ext-link-type="uri" xlink:href="https://stnava.github.io/ANTs/">https://stnava.github.io/ANTs/</ext-link>)<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>.</p>
<p id="Par14">A series of independent raters (two per measure) who were blinded to the participant age, group, and time point, quantitatively assessed all MR images for four measurements of brain morphology: MCP and superior cerebellar peduncle (SCP) widths as well as pons and midbrain cross-sectional areas based on methods previously described<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR50">50</xref></sup> and detailed below.</p>
<p id="Par15">The pons and midbrain areas were assessed on the mid-sagittal slice, where horizontal lines were drawn through the superior and inferior pontine notches. The midbrain was measured as the area above the superior pontine line – midbrain tegmentum, while the pons was the area between the two horizontal lines of the superior and inferior notches. The width of both left and right MCPs were measured on parasagittal slices. The linear distance of the MCP was delineated by the peripeduncular cerebrospinal fluid spaces of pontocerebellar cisterns, where the pons was still ‘intact’ and the cerebellum was fully formed (white matter connecting the cerebellar tonsil was present). Finally, the widths of both the left and right SCPs were measured on oblique coronal slices, at the midpoint of the SCP, when it first became separated from the inferior colliculi. The linear distance between the medial and lateral SCP borders was measured. For both MCP and SCP widths, a mean score was calculated by averaging the left and right measurements for each participant. The interrater reliability coefficients were excellent, greater than 0.98, for each of the four measurements. The mean score of the raters was used for further analysis.</p>
</sec>
<sec id="Sec7">
<title>Statistical analysis</title>
<p id="Par16">Statistical Analyses were conducted blind to treatment groups using R, version 3.6.0. Age and CGG repeat numbers were compared between groups using ANOVA F-tests, followed by pairwise comparisons in the event of a significant F test. The association between mRNA expression and CGG repeat length in each group, adjusted for age, was analyzed using linear models with CGG repeat length, group, the interaction between CGG repeat length and group, and age as covariates. mRNA expression was compared between groups, adjusting for age, using linear models with group and age as covariates. The change between timepoint 1 and time point 2 in mRNA expression was compared between groups, adjusting for age and visit interval, using linear models with the group, age, and visit interval as covariates. The association between each brain measure and each molecular measure was analyzed at each time point within each group, adjusting for age, using linear models with molecular measure, group, the group–molecular measure interaction, and age as covariates. The association between changes in brain measures and changes in molecular measures, within each group, adjusting for age and visit interval, was analyzed using linear models including change in molecular measure, group, the group–molecular measure change interaction, age, and visit interval as covariates. mRNA and protein expression values were log-transformed prior to analysis in order to more closely satisfy model assumptions; brain measures were analyzed on their original scale. Due to the exploratory nature of this study, no adjustment for multiple testing was conducted<sup><xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup>. The tables of all analyses conducted are reported in the supplemental materials.</p>
</sec>
</sec>
<sec id="Sec8">
<title>Results</title>
<sec id="Sec9">
<title>Demographics</title>
<p id="Par17">Numbers of participants (N) for each group, age and CGG repeat number are as reported in (Table <xref ref-type="table" rid="Tab1">1</xref>). Participants ages did not differ significantly between the three groups. CGG repeat numbers were significantly lower in healthy controls than in all other groups, as expected (<italic>p</italic> &lt; 0.001 in both comparisons) and were not significantly different between converters and non-converters (<italic>p</italic> = 0.445).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Participants baseline characteristics by group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"></th><th align="left">Healthy control</th><th align="left">Converters</th><th align="left">Non-converters</th><th align="left">All participants</th><th align="left"><italic>p</italic> Value (F-test)</th></tr></thead><tbody><tr><td align="left" colspan="6"><bold>Age</bold></td></tr><tr><td align="left">N</td><td align="left">15</td><td align="left">15</td><td align="left">15</td><td align="left">45</td><td align="char" char="." rowspan="3">0.936</td></tr><tr><td align="left">Mean (SD)</td><td align="left">60.1 (6.7)</td><td align="left">61 (6.7)</td><td align="left">60.7 (6.4)</td><td align="left">60.6 (6.4)</td></tr><tr><td align="left">Median (range)</td><td align="left">60 (49–69)</td><td align="left">61 (52–72)</td><td align="left">62 (47–70)</td><td align="left">61 (47–72)</td></tr><tr><td align="left" colspan="6"><bold>CGG</bold></td></tr><tr><td align="left">N</td><td align="left">15</td><td align="left">15</td><td align="left">15</td><td align="left">45</td><td align="char" char="." rowspan="3"> &lt; 0.001</td></tr><tr><td align="left">Mean (SD)</td><td align="left">28.5 (4.1)</td><td align="left">90.1 (22.4)</td><td align="left">81.9 (22.1)</td><td align="left">66.9 (32.9)</td></tr><tr><td align="left">Median (range)</td><td align="left">30 (20–32)</td><td align="left">84 (60–141)</td><td align="left">78 (56–135)</td><td align="left">75 (20–141)</td></tr></tbody></table></table-wrap>
</p>
</sec>
<sec id="Sec10">
<title><italic>FMR1</italic> mRNA isoforms expression analysis</title>
<p id="Par18">We measured the expression of <italic>FMR1</italic> mRNA, <italic>FMR1</italic> isoforms <italic>Iso10/10b, Iso4/4b</italic>, <italic>IsoPB1.21, ASFMR1,</italic> and <italic>ASFMR1 Iso131</italic> at V1, V2 and between the visits (Supplementary Material Table <xref ref-type="media" rid="MOESM1">S2a</xref>, <xref ref-type="media" rid="MOESM1">S2b</xref> and <xref ref-type="media" rid="MOESM1">S2a</xref>). As expected, the expression of <italic>FMR1</italic> mRNA was significantly higher in both converters and non-converters as compared to non-carrier healthy controls both at V1 (<italic>p</italic> &lt; 0.001) and V2 (<italic>p</italic> &lt; 0.001) but no significant differences were observed between the two premutation groups (Fig. <xref ref-type="fig" rid="Fig2">2</xref>a.). <italic>FMR1</italic> expression levels were associated with CGG repeat length, with greater expression levels being associated with longer CGG repeat length, in both converters and non-converters compared to non-carrier healthy controls (<italic>p</italic> &lt; 0.001 for both comparisons; Fig. <xref ref-type="fig" rid="Fig2">2</xref>b.).<fig id="Fig2"><label>Figure 2</label><caption><p><italic>FMR1</italic> mRNA expression among groups and by CGG repeat length. <bold>a</bold> Box plots showing increased expression levels of <italic>FMR1</italic> mRNA in both premutation groups (converters and non-converters) compared to non-carrier healthy controls at V1 (<italic>p</italic> &lt; 0.001) and V2 (<italic>p</italic> &lt; 0.001) but no significant differences were observed between the two premutation groups. The heavy line in each box represents the median, the lower and upper box edges represent the 25th and 75th percentiles, respectively, and the lower and upper whiskers represent the smallest and largest observations, respectively. <bold>b</bold> Scatter plots showing <italic>FMR1</italic> mRNA expression as function of CGG repeat number at V1 in the three groups.</p></caption><graphic id="MO2" xlink:href="41598_2020_67946_Fig2_HTML"></graphic></fig>
</p>
<p id="Par19">The expression levels of Iso<italic>10/ Iso10b,</italic> CGG dependent (Fig. <xref ref-type="fig" rid="Fig3">3</xref>d) were significantly higher in converters at V1 (<italic>p</italic> = 0.022) and V2 (<italic>p</italic> = 0.046) respectively, as compared to non-carrier healthy controls. Importantly, these markers were not significantly different in non-converters as compared to non-carrier healthy controls at either V1 (<italic>p</italic> = 0.401) or V2 (<italic>p</italic> = 0.592) (Fig. <xref ref-type="fig" rid="Fig3">3</xref>a). For <italic>Iso4/4b</italic> we observed significantly higher expression in converters as compared to non-carrier healthy controls at V1 (<italic>p</italic> = 0.032) but no difference was found at V2 (<italic>p</italic> = 0.247) and with the CGG repeat number (Fig. <xref ref-type="fig" rid="Fig3">3</xref>e).The expression of these isoforms was not significantly different in non-converters as compared to non-carrier healthy controls both at V1 (<italic>p</italic> = 0.542) and V2 (<italic>p</italic> = 0.684) (Fig. <xref ref-type="fig" rid="Fig3">3</xref>b). The expression levels of additional transcripts encoding for truncated proteins, <italic>IsoPB1.21 and IsoPB1.50</italic> were not significantly different among groups both at V1 or V2.<fig id="Fig3"><label>Figure 3</label><caption><p>Isoforms mRNA expression levels among three groups and as function of the CGG repeat number. <bold>a </bold>Box plots showing increased levels of <italic>FMR1 Iso10/10b</italic> mRNA at both V1 and V2 (<italic>p</italic> = 0.022 and <italic>p</italic> = 0.046 respectively) only in the converter group but not in the non-converter group (<italic>p</italic> = 0.401 at V1 and <italic>p</italic> = 0.592 at V2) compared to non-carrier healthy controls. <bold>b</bold> Box plots showing increased levels of <italic>FMR1 Iso4/4b mRNA</italic> at V1 (<italic>p</italic> = 0.032) but not at V2 (<italic>p</italic> = 0.247) in the converter group compared to non-carrier healthy controls. No differences were observed in the non-converter group at both visits (<italic>p</italic> = 0.542 at V1 and <italic>p</italic> = 0.684 at V2). <bold>c</bold> Box plots showing increased levels of <italic>ASFMR1 Iso131bp mRNA</italic> at both V1 (<italic>p</italic> &lt; 0.001) and V2 (<italic>p</italic> &lt; 0.001) in both the premutation groups compared to non-carrier healthy controls but not statistically significant differences between the two premutation groups. The heavy line in each box represents the median, the lower and upper box edges represent the 25th and 75th percentiles, respectively, and the lower and upper whiskers represent the smallest and largest observations, respectively. Scatter plots showing <bold>d</bold>
<italic>FMR1</italic>
<bold>e</bold> of <italic>FMR1 Iso4/4b</italic> and <bold>f</bold> of <italic>ASFMR1 Iso131bp</italic> mRNA expression levels as function of the CGG repeat number at V1 in the three groups.</p></caption><graphic id="MO3" xlink:href="41598_2020_67946_Fig3_HTML"></graphic></fig></p>
<p id="Par20">Significantly increased expression levels of <italic>ASFMR1 Iso131</italic> bp, CGG dependent (<italic>p</italic> = 0.012 for the non-converter group and <italic>p</italic> = 0.05 for the converter group; Fig. <xref ref-type="fig" rid="Fig3">3</xref>f) were observed in the premutation groups, both converters, and non-converters, as compared to non-carrier healthy controls both at V1 (<italic>p</italic> &lt; 0.001) and V2 (<italic>p</italic> &lt; 0.001) with no difference in levels between the two premutation groups (Fig. <xref ref-type="fig" rid="Fig3">3</xref>c).</p>
<p id="Par21">However, when comparing the changes in the gene expression levels between V1 and V2 we found a significant greater change in the expression of <italic>ASFMR1 Iso131 bp</italic> in converters (<italic>p</italic> = 0.006; Fig. <xref ref-type="fig" rid="Fig4">4</xref>) as compared to non-carrier healthy controls while no significant difference was observed between non-converters and non-carrier healthy controls (<italic>p</italic> = 0.102; Fig. <xref ref-type="fig" rid="Fig4">4</xref>).Finally, when comparing the expression levels at V1 and V2 among the groups, no significant differences were detected for any of the <italic>FMR1</italic> splicing isoforms or the <italic>ASFMR1</italic> gene.<fig id="Fig4"><label>Figure 4</label><caption><p>Changes in <italic>ASFMR1 Iso131bp</italic> expression levels between visits. Boxplots showing higher changes between V1 and V2 in the expression level of the <italic>ASFMR1 Iso131bp</italic> in the converter group as compared to non-carrier healthy controls while no significant change in non-converter versus control was observed. The heavy line in each box represents the median, the lower and upper box edges represent the 25th and 75th percentiles, respectively, and the lower and upper whiskers represent the smallest and largest observations, respectively.</p></caption><graphic id="MO4" xlink:href="41598_2020_67946_Fig4_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec11">
<title>Correlation between brain measures and molecular measures</title>
<p id="Par22">We compared brain measures, including MCP and SCP width, midbrain and pons cross-sectional area with the molecular measures at V1, V2 and between the visits (Supplementary Material Table <xref ref-type="media" rid="MOESM1">S3a</xref>, <xref ref-type="media" rid="MOESM1">S3B</xref> and <xref ref-type="media" rid="MOESM1">S3c</xref>). Changes in the measures of brain morphology were associated with the expression of some <italic>FMR1</italic> isoforms. Specifically, we found that the higher level of expression of the <italic>Iso4/4b</italic> mRNAs was associated with smaller MCP width in converters both at V1 (<italic>p</italic> = 0.028, beta = -0.421; Fig. <xref ref-type="fig" rid="Fig5">5</xref>a). and V2 (<italic>p</italic> = 0.048, beta = -0.531; Fig. <xref ref-type="fig" rid="Fig5">5</xref>b) but not in the non-converters at both V1( <italic>p</italic> = 0.611, beta = -0.064; Fig. <xref ref-type="fig" rid="Fig5">5</xref>a) or V2 (<italic>p</italic> = 0.333, beta = – 0.392; Fig. <xref ref-type="fig" rid="Fig5">5</xref>b) and not in the healthy controls (<italic>p</italic> = 0.530, V1; beta = 0.085; <italic>p</italic> = 0.365, beta = – 0.376). Further, the expression of the <italic>ASFMR1</italic> isoform (131 bp) also increased significantly with a decrease in changes in the pons (<italic>p</italic> = 0.047, beta = – 0.012) only in the converter group between V1 and V2.<fig id="Fig5"><label>Figure 5</label><caption><p>Molecular and brain measure correlations. Scatter plots demonstrating an inverse correlation between the mean MCP width and Iso4/4b in both V1 and V2 but only in the converter group while no significant correlation was observed in the non-converter group.</p></caption><graphic id="MO5" xlink:href="41598_2020_67946_Fig5_HTML"></graphic></fig></p>
<p id="Par23">Finally, we found a positive correlation, between the change in brain measures, including the mean SCP (<italic>p</italic> = 0.017, beta = 0.726) and midbrain area (<italic>p</italic> = 0.031, beta = 0.316) with increased expression of the <italic>FMR1</italic> mRNA, between the two visits only in the converter group. We also found that the expression of <italic>Iso10/10b</italic> increased significantly with an increase with changes in the midbrain area (<italic>p</italic> = 0.045, beta = 0.076).</p>
</sec>
</sec>
<sec id="Sec12">
<title>Discussion</title>
<p id="Par24">Alternative Splicing (AS) is a common process in the central nervous system and crucial for the differentiation and physiology of cells, particularly neurons. It is estimated that AS occurs in about 95% of human genes<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>, contributing greatly to the regulation of mRNA levels and to proteomic diversity. Different studies have reported that AS events take place at the <italic>FMR1</italic> locus and have an impact on the expression and function of FMRP<sup><xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR54">54</xref>–<xref ref-type="bibr" rid="CR57">57</xref></sup> We recently reported on the characterization of the <italic>FMR1</italic> isoforms and showed differential expression and distribution as a function of the CGG repeat number in premutation carriers. Differently from the 24 predicted <italic>FMR1</italic> mRNA variants, we also reported on the existence, of at least 49 different ones in several human tissues, 30 of which detected only in premutation carriers<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. Thus, an altered alternative splicing phenomenon is present in premutation carriers.</p>
<p id="Par25">In this study, we aimed to identify molecular biomarkers, specifically the expression levels of some alternatively spliced isoforms at the <italic>FMR1</italic> locus, for risk prediction, early diagnosis, and progression of developing FXTAS. Increased and CGG dependent expression levels of <italic>FMR1</italic> mRNA were observed in premutation groups (including both converters and non-converters) as compared to non-carrier healthy controls confirming many previous reports on this well-established altered molecular phenotype in premutation carriers. In addition to <italic>FMR1 mRNA,</italic> we also observed elevated expression of various alternative splicing isoforms as a function of CGG repeat suggesting their potential contribution to the RNA toxicity in premutation carriers.</p>
<p id="Par26">Taking advantage of the longitudinal study design, we investigated the expression profile for these specific isoforms among our three groups and observed the higher expression of isoform <italic>Iso10/10b</italic> in converters as compared to non-carrier healthy controls at both visits. Importantly, the non-converter group did not show the differential expression for this isoform. This suggests that these isoforms, that encode for truncated proteins might be relevant in the pathogenesis of FXTAS and, pending replication and further confirmation, may eventually play a role in early testing and screening of premutation allele carriers at greater risk of developing the disorder.</p>
<p id="Par27">Previous investigations on the <italic>FMR1</italic> transcriptional landscape reported the highest expression of isoform <italic>Iso10/10b</italic> in premutation carriers with and without FXTAS<sup><xref ref-type="bibr" rid="CR15">15</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. However, this study shows a higher expression of these isoforms in individuals, in the converter group, who develop FXTAS over time. Similarly, we observed higher expression of the isoforms <italic>Iso4/4b,</italic> which encode for truncated proteins and are therefore missing the nuclear export signal and C-terminal RGG box, in the converter group, but not in the non-converter group, as compared to healthy controls, also suggesting the potential role of truncated proteins in the pathogenesis of FXTAS, which needs to be further investigated.</p>
<p id="Par28">The midbrain, pons, and superior cerebellar peduncles (SCP) atrophy is the characteristic pathologic finding in patients with a number of neurodegenerative disorders including progressive supranuclear palsy (PSP)<sup><xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR59">59</xref></sup>, Parkinson's disease (PD), Multiple System Atrophy (MSA)<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR60">60</xref></sup> and Alzheimer's disease<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>. These studies have proposed a number of midbrain metrics as potential biomarkers for differentiation of the patients with different neurodegenerative conditions. Shelton et al.<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> suggested that the decreased MCP width observed in the premutation carriers who developed FXTAS over time (converters) could be a biomarker for early identification of incipient FXTAS. Of relevance, this study found a significant association of increased expression of Iso<italic>4/4b</italic> with decreased MCP width and of the expression of <italic>ASFMR1</italic> isoform (131 bp) with decreased changes in pons, only in the converter group, which supports their potential role as biomarkers and support evidence of their potential contribution to the pathogenesis of the disorder. Interestingly, in the current study we found a positive association of <italic>FMR1</italic> mRNA with mean SCP and midbrain and of isoform <italic>Iso10/10b</italic> with the midbrain, suggesting that some of the molecular measures may be linked with the changes in the brain structures. However, further studies are warranted to confirm these findings.</p>
<p id="Par29">Generally, the mRNAs containing premature termination codons (PTCs) are degraded by the nonsense-mediated mRNA decay (NMD) system. However, this is not always the case as sometimes the mRNAs escape from the nonsense-mediated mRNA decay and results in truncated proteins<sup><xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup>. Truncated proteins can form aggregates and can act in a dominant-negative manner. The accumulation of these abnormal truncated proteins leads to the gradual loss of function and structure of neurons including the death of neurons. These aggregations have been found to be associated with various neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s diseases, ASD, and amyotrophic lateral sclerosis. Additionally, a truncated form of <italic>DISC1</italic> aggregates has been associated with major depression and schizophrenia<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>. Thus, it is possible that the translation of these isoforms might contribute to the pathogenesis of the <italic>FMR1</italic> associated disorders. However, the exact mechanism and functional role are still unknown.</p>
<p id="Par30">The previous report suggested that the antisense <italic>FMR1</italic> (<italic>ASFMR1</italic>) gene and the premutation specific <italic>ASFMR1 Iso131</italic> bp may contribute to the pathogenesis of FXTAS<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. Although the expression of this splice isoform in premutation carriers was reported to be higher compared to controls, no difference in the expression levels was observed between non-FXTAS and FXTAS premutation carrier groups in previous studies<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup>. The study presented here confirms the previous findings of a higher expression of this splice isoform in premutation carriers; however and importantly, the observed significant change of expression levels between V1 and V2 only in the converter group but not in the non-converter or control groups, suggest its potential role in the progression of FXTAS. These findings suggest the presence of an altered bidirectional transcription alternative splicing in premutation carriers and their potential role in the development and progression of FXTAS.</p>
<p id="Par31">Finally, further studies are required to investigate the function of this specific isoform. The longitudinal follows up of these individuals may help our understanding of the potential role of such isoforms in FXTAS.</p>
</sec>
<sec id="Sec13">
<title>Conclusions</title>
<p id="Par32">In conclusion, this is a first study that provides evidence of an elevated expression of some of the <italic>FMR1</italic> and <italic>ASFMR1</italic> mRNA splicing isoforms is present in premutation carriers who develop FXTAS compared to those who remain symptom free and to controls, providing support for these measures as potential biomarkers for early identification and monitoring of disease progression. In addition, the association of these molecular measures with brain measures provide us better insight regarding disease pathogenesis. However, due to limitation of the small sample size in the present study, further studies with larger sample size are required to replicate our initial findings and elucidate and confirm the role of these potential biomarkers.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary information</title>
<sec id="Sec15">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2020_67946_MOESM1_ESM.xlsx"><caption><p>Supplementary Data</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p>
<bold>Publisher's note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<sec>
<title>Supplementary information</title>
<p>is available for this paper at 10.1038/s41598-020-67946-y.</p>
</sec>
<ack>
<title>Acknolwedgements</title>
<p>We thank the participants of the community‐based studies who donated their time and sample for this study. This paper is dedicated to the memory of Matteo. This study was funded by the National Institute of Health RO1NS110100-11/RO1MH078041, and grants of UL1 TR001860 and U54 HD079125.</p>
</ack>
<notes notes-type="author-contribution">
<title>Author contributions</title>
<p>F.T., D.H. and S.M.R. designed the study; M.Z., H.-T.T. and E.F. performed the practical work and collected the data; B.D.-J. performed statistical analyses; M.Z. and F.T. drafted the manuscript. All listed authors have read and critically revised drafts for intellectual contents and provided full approval for publication.</p>
</notes>
<notes notes-type="data-availability">
<title>Data Availbility</title>
<p>All statistical data generated during the study is available in the Additional File.xlsx titled “Supplementary Data”.</p>
</notes>
<notes id="FPar1" notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par34">Dr. Flora Tassone received funding from Zynerba and Azrieli Foundation for carrying out studies in Fragile X Syndrome. Dr. David Hessl received the funding from Zynerba and Ovid Therapeutics regarding fragile X syndrome clinical trials. The other authors authors declare no competing interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hazlett</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>DB</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Moine</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kooy</surname>
<given-names>RF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fragile X syndrome</article-title>
<source/>Nat. Rev. Dis. Primers.
          <year>2017</year>
<volume>3</volume>
<fpage>17065</fpage>
<pub-id pub-id-type="doi">10.1038/nrdp.2017.65</pub-id>
<pub-id pub-id-type="pmid">28960184</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Fragile X syndrome and fragile X-associated tremor ataxia syndrome</article-title>
<source/>Handb. Clin. Neurol.
          <year>2018</year>
<volume>147</volume>
<fpage>377</fpage>
<lpage>391</lpage>
<pub-id pub-id-type="doi">10.1016/B978-0-444-63233-3.00025-7</pub-id>
<pub-id pub-id-type="pmid">29325626</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fink</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Pyeritz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fragile X associated primary ovarian insufficiency (FXPOI): case report and literature review</article-title>
<source/>Front Genet.
          <year>2018</year>
<volume>9</volume>
<fpage>529</fpage>
<pub-id pub-id-type="doi">10.3389/fgene.2018.00529</pub-id>
<pub-id pub-id-type="pmid">30542367</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacquemont</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Penetrance of the fragile X–associated tremor/ataxia syndrome in a premutation carrier population</article-title>
<source/>JAMA.
          <year>2004</year>
<pub-id pub-id-type="doi">10.1001/jama.291.4.460</pub-id>
<pub-id pub-id-type="pmid">14747503</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Iong</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>T-H</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gane</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States</article-title>
<source/>Genom. Med.
          <year>2012</year>
<pub-id pub-id-type="doi">10.1186/gm401</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Gane</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Godfrey</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome</article-title>
<source/>Am. J. Hum. Genet.
          <year>2000</year>
<pub-id pub-id-type="doi">10.1086/302720</pub-id>
<pub-id pub-id-type="pmid">10631132</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagerman</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Fragile X-associated tremor/ataxia syndrome — features, mechanisms and management</article-title>
<source/>Nat Rev. Neurol.
          <year>2016</year>
<pub-id pub-id-type="doi">10.1038/nrneurol.2016.82</pub-id>
<pub-id pub-id-type="pmid">27340021</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashley</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Reines</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>FMR1 protein: conserved RNP family domains and selective RNA binding</article-title>
<source/>Science.
          <year>1993</year>
<pub-id pub-id-type="doi">10.1126/science.7692601</pub-id>
<pub-id pub-id-type="pmid">7692601</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verheij</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bakker</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>de Graaff</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Keulemans</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Willemsen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Annemieke</surname>
<given-names>JM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Characterization and localization of the FMR-1 gene product associated with fragile X syndrome</article-title>
<source/>Nature.
          <year>1993</year>
<pub-id pub-id-type="doi">10.1038/363722a0</pub-id>
<pub-id pub-id-type="pmid">8515814</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verkerk</surname>
<given-names>AJMH</given-names>
</name>
<name>
<surname>Annemieke</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>de Graaff</surname>
<given-names>E</given-names>
</name>
<name>
<surname>De Boulle</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Konecki</surname>
<given-names>DS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alternative splicing in the fragile X gene FMR1</article-title>
<source/>Hum. Mol. Genet.
          <year>1993</year>
<pub-id pub-id-type="doi">10.1093/hmg/2.4.399</pub-id>
<pub-id pub-id-type="pmid">8401531</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<mixed-citation publication-type="other">Huang, T., Li, L.-Y., Shen, Y., Qin, X.-B., Pang, Z.-L., Wu, G.-Y. Alternative splicing of the FMR1 gene in human fetal brain neurons. <italic>Am. J. Med. Genet</italic>. 10.1002/(SICI)1096-8628(19960809)64:2&lt;252::AID-AJMG3&gt;3.0.CO;2-W (1996).</mixed-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sittler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Devys</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>C-L</given-names>
</name>
<name>
<surname>Mandel</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Alternative splicing of Exon 14 determines nuclear or cytoplasmic localisation of FMR1 protein isoforms</article-title>
<source/>Hum. Mol. Genet.
          <year>1996</year>
<pub-id pub-id-type="doi">10.1093/hmg/5.1.95</pub-id>
<pub-id pub-id-type="pmid">8789445</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Dolzhanskaya</surname>
<given-names>N</given-names>
</name>
<name>
<surname>LaFauci</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Dobkin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Denman</surname>
<given-names>RB</given-names>
</name>
</person-group>
<article-title>Tissue and developmental regulation of fragile X mental retardation 1 exon 12 and 15 isoforms</article-title>
<source/>Neurobiol. Dis.
          <year>2009</year>
<volume>35</volume>
<fpage>52</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2009.03.015</pub-id>
<pub-id pub-id-type="pmid">19362146</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brackett</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Qing</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Amieux</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Sellers</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Horner</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>FMR1 transcript isoforms: association with polyribosomes; regional and developmental expression in mouse brain</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<fpage>e58296</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0058296</pub-id>
<pub-id pub-id-type="pmid">23505481</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pretto</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Eid</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Yrigollen</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H-T</given-names>
</name>
<name>
<surname>Loomis</surname>
<given-names>EW</given-names>
</name>
<name>
<surname>Raske</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differential increases of specificFMR1mRNA isoforms in premutation carriers</article-title>
<source/>J. Med. Genet.
          <year>2015</year>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2014-102593</pub-id>
<pub-id pub-id-type="pmid">25358671</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<mixed-citation publication-type="other">Tseng, E., Tang, H.-T., AlOlaby, R.R., Hickey, L., Tassone, F. Altered expression of the FMR1 splicing variants landscape in premutation carriers. <italic>Biochim. Biophysica Acta (BBA) Gene Regul. Mech</italic>. 10.1016/j.bbagrm.2017.08.007. (2017).</mixed-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelemen</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Convertini</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Falaleeva</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Function of alternative splicing</article-title>
<source/>Gene
          <year>2013</year>
<volume>514</volume>
<fpage>1</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2012.07.083</pub-id>
<pub-id pub-id-type="pmid">22909801</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname>
<given-names>C-H</given-names>
</name>
<name>
<surname>Dhananjaya</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tarn</surname>
<given-names>W-Y</given-names>
</name>
</person-group>
<article-title>Alternative splicing in neurogenesis and brain development</article-title>
<source/>Front. Mol. Biosci.
          <year>2018</year>
<pub-id pub-id-type="doi">10.3389/fmolb.2018.00012</pub-id>
<pub-id pub-id-type="pmid">29484299</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raj</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Blencowe</surname>
<given-names>BJ</given-names>
</name>
</person-group>
<article-title>Alternative splicing in the mammalian nervous system: recent insights into mechanisms and functional roles</article-title>
<source/>Neuron
          <year>2015</year>
<volume>87</volume>
<fpage>14</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2015.05.004</pub-id>
<pub-id pub-id-type="pmid">26139367</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paronetto</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Passacantilli</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Sette</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Alternative splicing and cell survival: from tissue homeostasis to disease</article-title>
<source/>Cell Death Differ.
          <year>2016</year>
<volume>23</volume>
<fpage>1919</fpage>
<lpage>1929</lpage>
<pub-id pub-id-type="doi">10.1038/cdd.2016.91</pub-id>
<pub-id pub-id-type="pmid">27689872</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Aberrant splicing in neurological diseases</article-title>
<source/>Wiley Interdiscipl. Rev. RNA.
          <year>2013</year>
<pub-id pub-id-type="doi">10.1002/wrna.1184</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cieply</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Carstens</surname>
<given-names>RP</given-names>
</name>
</person-group>
<article-title>Functional roles of alternative splicing factors in human disease</article-title>
<source/>Wiley Interdiscipl. Rev. RNA.
          <year>2015</year>
<pub-id pub-id-type="doi">10.1002/wrna.1276</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quesnel-Vallières</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dargaei</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Irimia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gonatopoulos-Pournatzis</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ip</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Misregulation of an activity-dependent splicing network as a common mechanism underlying autism spectrum disorders</article-title>
<source/>Mol. Cell.
          <year>2016</year>
<volume>64</volume>
<fpage>1023</fpage>
<lpage>1034</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2016.11.033</pub-id>
<pub-id pub-id-type="pmid">27984743</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cognata</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>La Cognata</surname>
<given-names>V</given-names>
</name>
<name>
<surname>D’Agata</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Cavalcanti</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cavallaro</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Splicing: is there an alternative contribution to Parkinson’s disease?</article-title>
<source/>Neurogenetics.
          <year>2015</year>
<pub-id pub-id-type="doi">10.1007/s10048-015-0449-x</pub-id>
<pub-id pub-id-type="pmid">25980689</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hutton</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lendon</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Rizzu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Froelich</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Houlden</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17</article-title>
<source/>Nature.
          <year>1998</year>
<pub-id pub-id-type="doi">10.1038/31508</pub-id>
<pub-id pub-id-type="pmid">9641683</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kashima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Manley</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>An intronic element contributes to splicing repression in spinal muscular atrophy</article-title>
<source/>Proc. Natl. Acad. Sci.
          <year>2007</year>
<pub-id pub-id-type="doi">10.1073/pnas.0700343104</pub-id>
<pub-id pub-id-type="pmid">17307868</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassidy</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Driscoll</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Prader-Willi syndrome</article-title>
<source/>Genet. Med.
          <year>2012</year>
<pub-id pub-id-type="doi">10.1038/gim.0b013e31822bead0</pub-id>
<pub-id pub-id-type="pmid">22237428</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stefansson</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rujescu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cichon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pietiläinen</surname>
<given-names>OPH</given-names>
</name>
<name>
<surname>Ingason</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Large recurrent microdeletions associated with schizophrenia</article-title>
<source/>Nature
          <year>2008</year>
<volume>455</volume>
<fpage>232</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.1038/nature07229</pub-id>
<pub-id pub-id-type="pmid">18668039</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mankodi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Moxley</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Thornton</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons</article-title>
<source/>Hum. Mol. Genet.
          <year>2004</year>
<pub-id pub-id-type="doi">10.1093/hmg/ddh327</pub-id>
<pub-id pub-id-type="pmid">15563508</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sreedharan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Blair</surname>
<given-names>IP</given-names>
</name>
<name>
<surname>Tripathi</surname>
<given-names>VB</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Vance</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rogelj</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TDP-43 Mutations in familial and sporadic amyotrophic lateral sclerosis</article-title>
<source/>Science.
          <year>2008</year>
<pub-id pub-id-type="doi">10.1126/science.1154584</pub-id>
<pub-id pub-id-type="pmid">18309045</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>H-X</given-names>
</name>
<name>
<surname>Siddique</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fecto</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia</article-title>
<source/>Neurology.
          <year>2010</year>
<pub-id pub-id-type="doi">10.1212/wnl.0b013e3181f07e0c</pub-id>
<pub-id pub-id-type="pmid">21172848</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koch</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Altered splicing in Alzheimer transcriptomes</article-title>
<source/>Nat. Rev. Genet.
          <year>2018</year>
<pub-id pub-id-type="doi">10.1038/s41576-018-0064-4</pub-id>
<pub-id pub-id-type="pmid">30341439</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khalil</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Faghihi</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Modarresi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Brothers</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Wahlestedt</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome</article-title>
<source/>PLoS ONE
          <year>2008</year>
<volume>3</volume>
<fpage>e1486</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0001486</pub-id>
<pub-id pub-id-type="pmid">18213394</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pastori</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Peschansky</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Barbouth</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Wahlestedt</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Comprehensive analysis of the transcriptional landscape of the human FMR1 gene reveals two new long noncoding RNAs differentially expressed in Fragile X syndrome and Fragile X-associated tremor/ataxia syndrome</article-title>
<source/>Hum. Genet.
          <year>2014</year>
<volume>133</volume>
<fpage>59</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-013-1356-6</pub-id>
<pub-id pub-id-type="pmid">24005575</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ladd</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Rabaia</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Georges</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Scott Hansen</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals</article-title>
<source/>Hum. Mol. Genet.
          <year>2007</year>
<pub-id pub-id-type="doi">10.1093/hmg/ddm293</pub-id>
<pub-id pub-id-type="pmid">17921506</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olaby</surname>
<given-names>RRA</given-names>
</name>
<name>
<surname>Al Olaby</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>H-T</given-names>
</name>
<name>
<surname>Durbin-Johnson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hessl</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Assessment of molecular measures in non-FXTAS male premutation carriers</article-title>
<source/>Front. Genet.
          <year>2018</year>
<pub-id pub-id-type="doi">10.3389/fgene.2018.00302</pub-id>
<pub-id pub-id-type="pmid">30186307</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vittal</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pandya</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Berry-Kravis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ASFMR1splice variant</article-title>
<source/>Neurol. Genet.
          <year>2018</year>
<pub-id pub-id-type="doi">10.1212/nxg.0000000000000246</pub-id>
<pub-id pub-id-type="pmid">30065951</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loesch</surname>
<given-names>DZ</given-names>
</name>
<name>
<surname>Godler</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bui</surname>
<given-names>QM</given-names>
</name>
<name>
<surname>Gehling</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kotschet</surname>
<given-names>KE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evidence for the toxicity of bidirectional transcripts and mitochondrial dysfunction in blood associated with small CGG expansions in the FMR1 gene in patients with parkinsonism</article-title>
<source/>Genet. Med.
          <year>2011</year>
<volume>13</volume>
<fpage>392</fpage>
<lpage>399</lpage>
<pub-id pub-id-type="doi">10.1097/GIM.0b013e3182064362</pub-id>
<pub-id pub-id-type="pmid">21270637</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shelton</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Fourie</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Frizzi</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Middle cerebellar peduncle width—a novel MRI biomarker for FXTAS?</article-title>
<source/>Front. Neurosci.
          <year>2018</year>
<pub-id pub-id-type="doi">10.3389/fnins.2018.00379</pub-id>
<pub-id pub-id-type="pmid">29988561</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramnani</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>The primate cortico-cerebellar system: anatomy and function</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2006</year>
<volume>7</volume>
<fpage>511</fpage>
<lpage>522</lpage>
<pub-id pub-id-type="doi">10.1038/nrn1953</pub-id>
<pub-id pub-id-type="pmid">16791141</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emamzadeh</surname>
<given-names>FN</given-names>
</name>
<name>
<surname>Surguchov</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Parkinson’s disease: biomarkers, treatment, and risk factors</article-title>
<source/>Front. Neurosci.
          <year>2018</year>
<pub-id pub-id-type="doi">10.3389/fnins.2018.00612</pub-id>
<pub-id pub-id-type="pmid">30214392</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bacalman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Farzin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bourgeois</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Cogswell</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Goodlin-Jones</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Gane</surname>
<given-names>LW</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia</article-title>
<source/>J. Clin. Psychiat.
          <year>2006</year>
<volume>67</volume>
<fpage>87</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.v67n0112</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tassone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Amiri</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Hagerman</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations</article-title>
<source/>J. Mol. Diagnost.
          <year>2008</year>
<pub-id pub-id-type="doi">10.2353/jmoldx.2008.070073</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filipovic-Sadic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sah</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Krosting</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sekinger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome</article-title>
<source/>Clin. Chem.
          <year>2010</year>
<volume>56</volume>
<fpage>399</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1373/clinchem.2009.136101</pub-id>
<pub-id pub-id-type="pmid">20056738</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<mixed-citation publication-type="other">Tassone, F., Hagerman, R. J., Chamberlain, W. D., Hagerman, P. J. Transcription of the FMR1 gene in individuals with fragile X syndrome. <italic>Am. J. Med. Genet</italic>. 10.1002/1096-8628(200023)97:3&lt;195::AID-AJMG1037&gt;3.0.CO;2-R (2000).</mixed-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ardekani</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Bachman</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>Model-based automatic detection of the anterior and posterior commissures on MRI scans</article-title>
<source/>NeuroImage.
          <year>2009</year>
<pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.02.030</pub-id>
<pub-id pub-id-type="pmid">19264138</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<mixed-citation publication-type="other">Mori, S., Crain, B. J., Chacko, V. P., Van Zijl, P. C. M. Three-dimensional tracking of axonal projections in the brain by magnetic resonance imaging.<italic> Ann. Neurol</italic>. p. 265–9. 10.1002/1531-8249(199902)45:2&lt;265::AID-ANA21&gt;3.0.CO;2-3 (1999).</mixed-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<mixed-citation publication-type="other">Tustison, N. J., Avants, B. B., Cook, P. A., Zheng, Y., Egan, A., Yushkevich, P. A., <italic>et al.</italic> N4ITK: improved N3 bias correction. IEEE Trans. Med. Imaging. p. 1310–20. Available from: 10.1109/tmi.2010.2046908. (2010).</mixed-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quattrone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nicoletti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Messina</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fera</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Condino</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pugliese</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MR imaging index for differentiation of progressive supranuclear palsy from parkinson disease and the parkinson variant of multiple system atrophy</article-title>
<source/>Radiology.
          <year>2008</year>
<pub-id pub-id-type="doi">10.1148/radiol.2453061703</pub-id>
<pub-id pub-id-type="pmid">17991785</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicoletti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fera</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Condino</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Auteri</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Gallo</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Pugliese</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MR imaging of middle cerebellar peduncle width: differentiation of multiple system atrophy from parkinson disease</article-title>
<source/>Radiology.
          <year>2006</year>
<pub-id pub-id-type="doi">10.1148/radiol.2393050459</pub-id>
<pub-id pub-id-type="pmid">16714464</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Althouse</surname>
<given-names>AD</given-names>
</name>
</person-group>
<article-title>Adjust for multiple comparisons? It’s not that simple</article-title>
<source/>Ann. Thorac. Surg.
          <year>2016</year>
<pub-id pub-id-type="doi">10.1016/j.athoracsur.2015.11.024</pub-id>
<pub-id pub-id-type="pmid">27106412</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hurlbert</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Utts</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Coup de grâce for a tough old bull: “statistically significant” expires</article-title>
<source/>Am. Stat.
          <year>2019</year>
<pub-id pub-id-type="doi">10.1080/00031305.2018.1543616</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Shai</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Frey</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Blencowe</surname>
<given-names>BJ</given-names>
</name>
</person-group>
<article-title>Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing</article-title>
<source/>Nat Genet.
          <year>2008</year>
<pub-id pub-id-type="doi">10.1038/ng.259</pub-id>
<pub-id pub-id-type="pmid">18978789</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashley</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Sutcliffe</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Kunst</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Leiner</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>DL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human and murine FMR-1: alternative splicing and translational initiation downstream of the CGG–repeat</article-title>
<source/>Nat. Genet.
          <year>1993</year>
<pub-id pub-id-type="doi">10.1038/ng0793-244</pub-id>
<pub-id pub-id-type="pmid">8358432</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Shen Y [Alternative splicing of the FMR1 gene in human fetal tissues]</article-title>
<source/>Zhongguo Yi Xue Ke Xue Yuan Xue Bao
          <year>1997</year>
<volume>19</volume>
<fpage>241</fpage>
<lpage>246</lpage>
<pub-id pub-id-type="pmid">10453560</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banerjee</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schoenfeld</surname>
<given-names>BP</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Hinchey</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Short- and long-term memory are modulated by multiple isoforms of the fragile X mental retardation protein</article-title>
<source/>J. Neurosci.
          <year>2010</year>
<pub-id pub-id-type="doi">10.1523/jneurosci.6369-09.2010</pub-id>
<pub-id pub-id-type="pmid">21068294</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alternatively spliced products lacking exon 12 dominate the expression of fragile X mental retardation 1 gene in human tissues</article-title>
<source/>Mol. Med. Rep.
          <year>2015</year>
<pub-id pub-id-type="doi">10.3892/mmr.2015.3574</pub-id>
<pub-id pub-id-type="pmid">26719067</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saeed</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Compagnone</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Aviv</surname>
<given-names>RI</given-names>
</name>
<name>
<surname>Strafella</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>AE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes: current and emerging concepts</article-title>
<source/>Transl. Neurodegener.
          <year>2017</year>
<pub-id pub-id-type="doi">10.1186/s40035-017-0076-6</pub-id>
<pub-id pub-id-type="pmid">28360997</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mangesius</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hussl</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krismer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mahlknecht</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Reiter</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tagwercher</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP</article-title>
<source/>Parkinsonism Relat. Disord.
          <year>2018</year>
<volume>46</volume>
<fpage>47</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1016/j.parkreldis.2017.10.020</pub-id>
<pub-id pub-id-type="pmid">29126761</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whitwell</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Höglinger</surname>
<given-names>GU</given-names>
</name>
<name>
<surname>Antonini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bordelon</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Boxer</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Colosimo</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?</article-title>
<source/>Mov. Disord.
          <year>2017</year>
<volume>32</volume>
<fpage>955</fpage>
<lpage>971</lpage>
<pub-id pub-id-type="doi">10.1002/mds.27038</pub-id>
<pub-id pub-id-type="pmid">28500751</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Andreescu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Aizenstein</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>HK</given-names>
</name>
</person-group>
<article-title>Brainstem morphological changes in Alzheimer’s disease</article-title>
<source/>NeuroReport.
          <year>2015</year>
<pub-id pub-id-type="doi">10.1097/wnr.0000000000000362</pub-id>
<pub-id pub-id-type="pmid">26559729</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nogueira</surname>
<given-names>G</given-names>
</name>
<name>
<surname>da Costa</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Romão</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Nonsense-mediated mRNA decay in development, stress and cancer</article-title>
<source/>mRNA Metabol. Hum. Disease.
          <year>2019</year>
<pub-id pub-id-type="doi">10.1007/978-3-030-19966-1_3</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaffrey</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Nonsense-mediated RNA decay in the brain: emerging modulator of neural development and disease</article-title>
<source/>Nat. Rev. Neurosci..
          <year>2018</year>
<pub-id pub-id-type="doi">10.1038/s41583-018-0079-z</pub-id>
<pub-id pub-id-type="pmid">30410025</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korth</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Aggregated proteins in schizophrenia and other chronic mental diseases</article-title>
<source/>Prion.
          <year>2012</year>
<pub-id pub-id-type="doi">10.4161/pri.18989</pub-id>
<pub-id pub-id-type="pmid">23052009</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>